This Article Full Text Full Text (PDF) All Versions of this Article: 109/14/1789    most recent 01.CIR.0000118466.47982.CCv1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Niu, P. Articles by Nagai, R. Search for Related Content PubMed PubMed Citation Articles by Niu, P. Articles by Nagai, R. Pubmed/NCBI databases Gene GEO Profiles HomoloGene UniGene Compound via MeSH Substance via MeSH Related Collections Cardio-renal physiology/pathophysiology Animal models of human disease Genetically altered mice Hypertrophy

(Circulation. 2004;109:1789-1794.)
© 2004 American Heart Association, Inc.

Basic Science Reports

Protective Effects of Endogenous Adrenomedullin on Cardiac Hypertrophy, Fibrosis, and Renal Damage

Pei Niu, MD; Takayuki Shindo, MD, PhD; Hiroshi Iwata, MD; Satoshi Iimuro, MD; Norifumi Takeda, MD; Yuelan Zhang, MD; Aya Ebihara, MD, PhD; Yoshihiro Suematsu, MD, PhD; Kenji Kangawa, PhD; Yasunobu Hirata, MD, PhD; Ryozo Nagai, MD, PhD

From the Department of Cardiovascular Medicine (P.N., T.S., H.I., S.I., N.T., Y.Z., A.E., Y.H., R.N.) and Cardiothoracic Surgery (Y.S.), Graduate School of Medicine, University of Tokyo, Tokyo, Japan, and National Cardiovascular Center Research Institute (K.K.), Osaka, Japan.

Correspondence to Takayuki Shindo, MD, PhD, Department of Cardiovascular Medicine, Graduate School of Medicine, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan. E-mail shindo-tky{at}umin.ac.jp

Received May 22, 2003; de novo received September 8, 2003; revision received November 11, 2003; accepted November 20, 2003.

Background— Adrenomedullin (AM) is a novel vasodilating peptide thought to have important effects on cardiovascular function. The aim of this study was to assess the activity of endogenous AM in the cardiovascular system using AM knockout mice.

Methods and Results— Mice heterozygous for an AM-null mutation (AM+/–) and their wild-type littermates were subjected to aortic constriction or angiotensin II (Ang II) infusion. The resultant cardiovascular stress led to increases in heart weight/body weight ratios, left ventricular wall thickness, and perivascular fibrosis, as well as expression of genes encoding angiotensinogen, ACE, transforming growth factor-ß, collagen type I, brain natriuretic peptide, and c-fos. In addition, renal damage characterized by decreased creatinine clearance with glomerular sclerosis was noted. In all cases, the effects were significantly more pronounced in AM+/– mice. Hearts from adult mice subjected to aortic constriction showed enhanced extracellular signal-regulated kinase (ERK) activation, as did cardiac myocytes from neonates treated acutely with Ang II. Again the effect was more pronounced in AM+/– mice, which showed increases in cardiac myocyte size, protein synthesis, and fibroblast proliferation. ERK activation was suppressed by protein kinase C inhibition to a greater degree in AM+/– myocytes. In addition, treatment of cardiac myocytes with recombinant AM suppressed Ang II-induced ERK activation via a protein kinase A-dependent pathway.

Conclusions— Endogenous AM exerts a protective effect against stress-induced cardiac hypertrophy via protein kinase C- and protein kinase A-dependent regulation of ERK activation. AM may thus represent a useful new tool for the treatment of cardiovascular disease.

Key Words: peptides • angiotensin • cardiovascular diseases • hypertrophy • kidney

This article has been cited by other articles:

				D. L. Sackett, L. Ozbun, E. Zudaire, L. Wessner, J. M. Chirgwin, F. Cuttitta, and A. Martinez Intracellular Proadrenomedullin-Derived Peptides Decorate the Microtubules and Contribute to Cytoskeleton Function Endocrinology, June 1, 2008; 149(6): 2888 - 2898. [Abstract] [Full Text] [PDF]

				R. T. Dackor, K. Fritz-Six, W. P. Dunworth, C. L. Gibbons, O. Smithies, and K. M. Caron Hydrops fetalis, cardiovascular defects, and embryonic lethality in mice lacking the calcitonin receptor-like receptor gene. Mol. Cell. Biol., April 1, 2006; 26(7): 2511 - 2518. [Abstract] [Full Text] [PDF]

				K. Miyashita, H. Itoh, H. Arai, T. Suganami, N. Sawada, Y. Fukunaga, M. Sone, K. Yamahara, T. Yurugi-Kobayashi, K. Park, et al. The Neuroprotective and Vasculo-Neuro-Regenerative Roles of Adrenomedullin in Ischemic Brain and Its Therapeutic Potential Endocrinology, April 1, 2006; 147(4): 1642 - 1653. [Abstract] [Full Text] [PDF]

				V. Vallon, D. Y. Huang, F. Grahammer, A. W. Wyatt, H. Osswald, P. Wulff, D. Kuhl, and F. Lang SGK1 as a determinant of kidney function and salt intake in response to mineralocorticoid excess Am J Physiol Regulatory Integrative Comp Physiol, August 1, 2005; 289(2): R395 - R401. [Abstract] [Full Text] [PDF]

				T. Nishikimi, K. Tadokoro, K. Akimoto, Y. Mori, Y. Ishikawa, K. Ishimura, T. Horio, K. Kangawa, and H. Matsuoka Response of adrenomedullin system to cytokine in cardiac fibroblasts-role of adrenomedullin as an antifibrotic factor Cardiovasc Res, April 1, 2005; 66(1): 104 - 113. [Abstract] [Full Text] [PDF]

				T. Tsuruda, J. Kato, K. Hatakeyama, H. Masuyama, Y.-N. Cao, T. Imamura, K. Kitamura, Y. Asada, and T. Eto Antifibrotic effect of adrenomedullin on coronary adventitia in angiotensin II-induced hypertensive rats Cardiovasc Res, March 1, 2005; 65(4): 921 - 929. [Abstract] [Full Text] [PDF]

				J. S. Swaney, D. M. Roth, E. R. Olson, J. E. Naugle, J. G. Meszaros, and P. A. Insel Inhibition of cardiac myofibroblast formation and collagen synthesis by activation and overexpression of adenylyl cyclase PNAS, January 11, 2005; 102(2): 437 - 442. [Abstract] [Full Text] [PDF]